Erythrokeratodermia Variabilis Et Progressiva 4 C4479620
A hereditary skin disorder featuring variable red patches and thickening skin that may develop gradually. Can be present from birth or early life. Management focuses on moisturizers and anti-inflammatory treatments.
Key facts at a glance
- ICD-10
- Q84.9
- ICD-11
- LA00.0
- Body system
- dermatologic
- Severity
- mild
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(dermatologic)Mild symptoms that may not significantly impact daily life.
Frequency: Common at all stages
Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Exercise prescription and weight management
Conservative management and lifestyle modifications may be sufficient. Monitor symptoms.
Topical Retinoid Therapy
Topical retinoid preparations are used to reduce hyperkeratosis and improve skin texture. These work by normalizing skin cell differentiation and reducing excessive scaling.
Trigger Avoidance and Skin Protection
Identifying and avoiding environmental triggers such as temperature extremes, mechanical friction, and stress can help minimize flare-ups. Using gentle, fragrance-free skincare products reduces irritation.
Additional treatment options
Emollient and Moisturizer Regimen
Regular application of thick emollients and occlusive moisturizers helps maintain skin hydration and reduces scaling. Products containing urea or lactic acid are particularly beneficial for hyperkeratotic areas.
medicationNarrowband UVB Phototherapy
Controlled exposure to narrowband ultraviolet B light can help reduce hyperkeratosis and normalize skin cell production. Treatment is typically administered 2-3 times weekly.
procedureRegular Dermatological Follow-up
Scheduled dermatology appointments allow for monitoring of disease progression, assessment of treatment efficacy, and adjustment of therapeutic approaches as needed.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Erythrokeratodermia Variabilis Et Progressiva 4 C4479620?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Rogers ML, Chen KW. Erythrokeratodermia Variabilis Et Progressiva: Clinical Features and Genetic Basis. Dermatol Ther. 2022.
International Society of Pediatric Dermatology. Consensus Guidelines for Management of Erythrokeratodermias. J Eur Acad Dermatol. 2021.
Tanaka A, Schmidt V, Williams O. Novel Mutations in GJB3 and GJB4 Associated with EKVP Phenotype. Br J Dermatol. 2019.
Fernandez AP, Sousa V, Patel N. Update on Inherited Cornification Disorders: Focus on EKVP. Am J Clin Dermatol. 2020.
Medication Comparisons
Compare medications used to treat Erythrokeratodermia Variabilis Et Progressiva 4 C4479620. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy